CRISPR-Based Gene Editing Offers Long-Term Reduction in Heart Disease Risk Factors
Researchers have developed a one-time treatment using CRISPR base editing delivered via lipid nanoparticles to permanently disable the ANGPTL3 gene in the liver, significantly lowering levels of LDL cholesterol and triglycerides. The approach showed high precision in human cells and nonhuman primates, with no detectable off-target effects or adverse structural changes. This strategy could transform chronic cardiovascular care by replacing daily medications with a single therapeutic intervention.
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering.” Browse more stories.